[NCI CIRB] MATCH - EAY131 - Molecular Analysis for Therapy Choice (MATCH)
The purpose of this trial is to establish whether participants with specific gene changes or mutations are likely to benefit if treated with study drugs targeting the genetic pathway.
Head and neck cancer
- Participants must have documented solid tumors, lymphoma, or multiple myeloma
- Participants must have progressed following at least 1 line of standard treatment
- Participants must receive lab results indicating a "rare variant" of interest for the study
18 - 100
Healthy Volunteers Needed
Duration of Participation
Participants will be on study for up to 3 years from the time of study entry through follow up.
Knight Information Line - email@example.com or 503-494-1080